PAR 1960 Reagenzienkatalog 2013-05-14 · cyflow ® counter Dedicated CD4 and CD4% counter for...

Reagentsmonoclonal antibodiesantibody PremixPartec reagents

illuminated by Partec. emitted for you.

2

Overview

dedi

cate

dGe

ner

al &

ded

icat

edflow cytometry

essential healthcare

microscopy

molecular diagnostics

cyflow® sPaceHigh-end FCM system for a wide range of applications with up to 16 optical parameters— 13 colors | 5 light sources_ optional Autoloading Station_ optional CyFlow® Sorter module

headQuarters

Partec GmbH Otto-Hahn-Straße 32 D-48161 Münster Germany

Phone +49 (0) 2534 8008-0 Fax +49 (0) 2534 8008-90 [email protected]

Partec GmbHAm Flugplatz 13D-02828 GörlitzGermany

Phone +49 (0) 3581 8746-0Fax +49 (0) 3581 8746-70 [email protected]

cyflow® cube 8High-end cost efficient FCM system with built-in monitor up to 8 optical parameters— 6 colors | 4 light sources_ optional Autoloading Station

cyflow® cube 6Compact and cost-efficient FCM system with built-in monitor 6 optical parameters—4 colors | 2 lasers_ optional Autoloading Station

cyflow® sl5 optical parameters—3 colours | 1 light sourceImmunology | Haematology | Pathology | Micro-biology Industrial Applications | Cell Biology

cyscoPe® research | hPHigh power LED microscope line: fluorescence and transmitted light, regular and inverted, portable | battery-operated, optional CMOS camera

cyflow® Ploidy analyserHigh resolution DNA analysis, ploidy analysis and genome Size with DAPI by UV LED and PI by green laser excitation_ optional Autoloading Station

cyfox® hd Gel electroPhoresis systemAll-in-one stand-alone system with live imaging for DNA/RNA analysis in molecular diagnostics & research. All components integrated in only one instrument, including micro computer and analysis software.

cyflow® counterDedicated CD4 and CD4% counter for routine HIV immune status monitoring and follow-up diagnostics of adult and pediatric AIDS patients_ optional Autopreparation &

Autoloading Station

cyflow® miniPocMobile / Point-of-care CD4 and CD4% counter for routine HIV immune status monitoring and follow-up dia gnostics of adult and pediatric AIDS patients

cyfox® hd Gel electroPhoresis systemAll-in-one stand-alone system with live imaging for DNA/RNA analysis in molecular diagnostics

3

Index

01 List of Mouse Monoclonal Antibodies Page 4

5 CD1a – CD235a 34 Mouse Isotype control 35 HLA-DR 37 Granzyme K 37 Annexin V

37 IL-6 37 Secondary Antibody 38 ds DNA 38 anti-FITC 38 Streptavidin

51 CyLyse® 51 Control Blood – dry 52 Rapid Malaria Test 52 CyStain® TB 53 OenoYeast™ 53 Yeast Control Viability 54 Yeast Control Glycogen 54 Yeast Control Trehalose 55 Yeast Control Neutral Lipids

47 CD4 easy count kit 47 CD4% easy count kit 48 CD4 easy count kit – dry 48 CD4% easy count kit – dry 49 CD3 easy count kit 49 CD8 easy count kit 50 miniPOC CD4% count kit – dry 50 CD4 easy count kit - dry – automate 50 CD4% easy count kit – dry – automate

04 Kits and Reagents Page 46

43 CD3/CD4/CD45 43 CD3/CD8/CD45 44 CD4/CD8/CD45 44 CD4/CD8/CD3

03 Antibody Premix for Triple Staining Page 42

41 CD3/CD4 41 CD3/CD8 41 CD4/CD8

02 Antibody Premix for Double Staining Page 40

• Medical Diagnostic/Immunology/Research• Essential Healthcare, HIV/AIDS, TB, Malaria• Microbiology/Industrial Applications• Agrosciences/Animal Research/Aquaculture• Quality Control

55 Yeast Control Cell Cycle 55 Sticky Control Reagent 56 CyStain® UV/CyStain® PI 58 CyStain® DNA/Protein 60 Quality Control 65 Consumables 67 Company

List of mouse monoclonal antibodies

4

(Please contact us for further information on antibodies not listed here)



5Hu: human, Ms: mouse, Pri: primate, Por: porcine, Bo: bovine, Can: canine*for 50 tests

cd1a FITC 05-7-123F 1 ml* IgG1 HI149 HuPE 05-7-123P 1 ml*

APC 05-7-123A 1 ml*

comment

CD1a, together with CD1b and c, belongs to group 1 of CD1 glycoproteins. These proteins serve as antigen-presenting molecules for a subset of T cells that responds to specific lipids and glycolipids found in the cell walls of bacterial pathogens or self-glycolipid an-tigens such as gangliosides, and they have also roles in antiviral immunity. Unlike CD1b, CD1a is excluded from late endosomal compartments and instead traffics independent-ly in the recycling pathway of the early endocytic system, and CD1a antigen presentation is independent on vesicular acidification.

The antibody HI149 reacts with CD1a (T6), a 49 KDa polypeptide associated with beta2-microglobulin expressed on cortical thymocytes (strongly), Langerhans cells, dendritic cells and some T cell leukaemias and lymphomas. The antibody does not react with peripheral blood T and B lymphocytes, monocytes, granulocytes, platelets and eryth-rocytes.

cd2 FITC 05-7-393F 1 ml* IgG2a LT2 HuPE 05-7-393P 1 ml*

APC 05-7-393A 1 ml*

FITC 05-7-502F 1 ml* IgG1 HIT11 Hu

PE 05-7-502P 1 ml*

comment

CD2 is a member of the immunoglobulin superfamily. Its interaction with CD58 stabi-lizes adhesion between T cells and antigen presenting cells. Relatively low affinity of CD2 to CD58 (as measured in solution) is compensated within the two-dimensional cell-cell interface to provide tight adhesion. Moreover T cell activation induces increased CD2 expression and its lateral mobility, making easier contact between CD2 and CD58. Subsequently T cell activation causes fixation of CD58-CD2 at sites of cell-cell contact, thereby strengthening intercellular adhesion. CD2 deficiency reduces intestinal inflam-mation and helps to control infection.

The antibody LT2 reacts with CD2, a 50 kDa glycoprotein present on human peripheral blood T and NK cells and is also expressed by all thymocytes.

The antibody HIT11 recognises a 50-kDa type-I single-chain transmembrane glyco-protein called LFA-2 (lymphocyte function associated antigen-2) or sheep red blood cell (SRBC) receptor. The CD2 antigen is expressed on 70-80% of peripheral blood lymphocytes and 80%-90% of thymocytes and NK cells. The primary ligand for CD2 is CD58 (LFA-3) despite binding to CD48, CD59 and CD15. The CD2 antigen plays a role in T cell signaling and in lymphocyte adhesion, and is an alternative pathway of T cell activation. There are two forms of CD2, a membrane form on cell surface and a soluble form in serum.

sPecificity format order no. Qty isotyPe clone reactivity examPle


6 Hu: human, Ms: mouse, Pri: primate, Por: porcine, Bo: bovine, Can: canine*for 50 tests

cd3 Purified 05-7-125 100 µg IgG2a MEM-57 HuFITC 05-7-125F 1 ml*

PE 05-7-125P 1 ml*

APC 05-7-125A 1 ml*

PE-Dy647 05-7-125 PD 647 1 ml*

Purified 05-7-411 100 µg IgG1 UCHT-1 Hu

FITC 05-7-411F 1 ml*

PE 05-7-411P 1 ml*

APC 05-7-411A 1 ml*

FITC 05-7-503F 1 ml* IgG1 HIT3b Hu

PE 05-7-503P 1 ml*

APC 05-7-503A 1 ml*

comment

CD3 complex is crucial in transducing antigen-recognition signals into the cytoplasm of T cells and in regulating the cell surface expression of the TCR complex. T cell activation through the antigen receptor (TCR) involves the cytoplasmic tails of the CD3 subunits CD3 gamma, CD3 delta, CD3 epsilon and CD3 zeta. These CD3 subunits are structurally related members of the immunoglobulins super family encoded by closely linked genes on human chromosome 11. The CD3 components have long cytoplasmic tails that associate with cytoplasmic signal transduction molecules. This association is mediated at least in part by a double tyrosine-based motif present in a single copy in the CD3 subunits. CD3 may play a role in TCR-induced growth arrest, cell survival and proliferation. The CD3 antigen is present on 68-82% of normal peripheral blood lymphocytes, 65-85% of thymocytes and Purkinje cells in the cerebellum. It is never expressed on B or NK cells. Decreased percentages of T lymphocytes may be observed in some autoimmune diseases.

The antibody MEM-57 reacts with gamma-epsilon and delta-epsilon dimers of human CD3 complex, a part of a bigger multisubunit T cell receptor complex (CD3/TCR) ex-pressed on peripheral blood T lymphocytes and mature thymocytes.

The antibody UCHT-1 recognises the CD3 antigen of the TCR/CD3 complex on mature human T cells. The UCHT-1 antibody reacts with the epsilon chain of the CD3 complex.

The antibody HIT3b recognises the 17-19 kDa ε-chain of CD3 within the CD3 antigen/T cell antigen receptor (TCR) complex. The CD3 antigen is expressed in the cell cytoplas-ma during the early stage of T cell development and is expressed on the cell membrane at the late stage.

for in-vitro diagnostic use


0.1 1 10 100 1000

500

400

300

200

100

0 cd3

Pe

ssc Analysed with CyFlow®



cd4 Purified 05-7-390 100 µg IgG2a EDU-2 HuFITC 05-7-390F 1 ml*

PE 05-7-390P 1 ml*

PE-Dy647 05-7-390 PD 647 1 ml*

APC 05-7-390A 1 ml*

Purified 05-7-128 100 µg IgG1 MEM-241 Hu

FITC 05-7-128F 1 ml*

PE 05-7-128P 1 ml*

PE-Dy647 05-7-128 PD 647 1 ml*

APC 05-7-128A 1 ml*

FITC 05-7-504F 1 ml* IgG2b HIT4a Hu

PE 05-7-504P 1 ml*

comment

CD4 is a single chain transmembrane glycoprotein belonging to the immunoglobulin superfamily. It has 4 immunoglobulin domains (1 Ig-Like V-type and 3 Ig-like C2- Type). The intracellular domain of CD4 is associated with p56Lck, a Src-like protein tyrosine kinase. It was described, that CD4 segregates into specific detergent-resistant T cell membrane microdomains. CD4 is a co-receptor involved in immune response (co-receptor activity in binding to MHC class II molecules) and HIV infection (human immu-nodeficiency virus; CD4 is a primary receptor for HIV-1 surface glycoprotein gp120). CD4 regulates T cell activation, T/B cell adhesion, T- cell differentiation, T cell selection and signal transduction. Defects in antigen presentation (MHC classII) cause dysfunction of CD4+ T cells and their almost complete absence in patients blood, tissue and organs (SCID immunodefiency).

The antibody MEM-241 recognises the CD4 antigen, a 55 kDa transmembrane glyco-protein expressed on a subset of T cells (helper T cells) and also on monocytes, tissue macrophages and granulocytes.

The antibody EDU-2 recognises the CD4 antigen, a 55 kDa transmembrane glycoprotein expressed on a subset of T lymphocytes (“helper” T cells) and also on monocytes, tissue macrophages and granulocytes.


cd5 FITC 05-7-397F 1 ml* IgG1 LT1 Hu

comment

CD5 is present on all mature T lymphocytes, on most thymocytes and on many T cell leukaemias and lymphomas. It reacts with a subpopulation of activated B cells. CD5/LT1 antigen is a monomeric type I transmembrane glycoprotein expressed on thymocytes, T lymphocytes, and a subset of B lymphocytes, but not on natural killer (NK) cells. It has been identified as the major ligand of the B cell antigen CD72. The frequency of CD5+ B cells exhibites strain dependent variation, and the phenotypic, ana-tomical, functional, developmental, and pathological characteristics of the CD5+ B cells suggest that they may represent a distinct lineage, known as B1 cells. Binding of CD5 on the T cell surface can augment alloantigen or mitogen induced lymphocyte proliferation and induces increased cytosolic free calcium, IL2 secretion, and IL2R expression. It has been proposed that CD5 negatively regulates signal transduction mediated by the T cell and B cell receptors.

The antibody LT1 reacts with the cell surface glycoprotein CD5, a 67kDa single-chain transmembrane glycoprotein expressed on mature T-lymphocytes, most of thymocytes and B-lymphocytes subset (subset 1a).


0.1 1 10 100 1000

500

400

300

200

100

0 cd

4 Pe




cd6 FITC 05-7-130F 1 ml* IgG1 MEM-98 HuPE 05-7-130P 1 ml*

PE-Dy647 05-7-130 PD 647 1 ml*

FITC 05-7-501F 1 ml* IgG1 HI210 Hu

comment

CD6, also known as T12, is a member of the scavenger receptor superfamily found on T and B cell subsets, thymocytes and acute lymphocytic leukaemia cells (ALL) and is involved in T cell development and activation, as well as thymocyte adhesion. CD6 inter-acts with CD166, also known as ALCAM. Gene location: human chromosome 11q13.

The MEM-98 antibody reacts with CD6, a 100-130 kDa single chain transmembrane glycoprotein expressed on T and B lymphocytes subsets, thymocytes, and acute lym-phocytic leukaemia cells.

The HI210 antibody reacts with CD6, a 100-130 kDa single chain transmembrane glyco-protein.

cd7 FITC 05-7-398F 1 ml* IgG2a LT7 Hu

comment

CD7 is expressed by the majority of thymocytes and mature T cells, NK cells and pre-B cells. It plays an essential role in T cell interactions and also in T cell/B cell interac-tion during early lymphoid development. The function of CD7 is not yet known although cross-linking of CD7 with antibodies induces a T cell transmembrane calcium flux and CD7 expression is induced by ionomycin. The CD7 molecule has been reported to be the receptor of the IgM-Fc portion (FcR mu) on the surface of T cells.

The LT7 antibody reacts with CD7, a 40 kDa type I transmembrane glycoprotein expressed on peripheral blood T lymphocytes, NK cells, haematopoietic progenitors, monocytes (weakly) and also on acute lymphocytic leukaemia.




cd8 FITC 05-7-132F 1 ml* IgG2a MEM-31 HuPE 05-7-132P 1 ml*

PE-Dy647 05-7-132 PD 647 1 ml*

APC 05-7-132A 1 ml*

Purified 05-7-498 100 µg IgG2a UCHT-4 Hu

FITC 05-7-498F 1 ml*

PE 05-7-498P 1 ml*

APC 05-7-498A 1 ml*

FITC 05-7-505F 1 ml* IgG1 HIT8a Hu

comment

The CD8 T cell coreceptor (monomer approx. 32-34 kDa) is expressed as alpha-beta heterodimer on majority of MHC I-restricted conventional T cells and thymocytes and as alpha-alpha homodimer on subsets of memory T cells, intraepithelial lymphocytes, NK cells and dendritic cells. Regulation of CD8 beta level on T cell surface seems to be an important mechanism to control their effector function. Assembly of CD8 alpha-beta but not alpha-alpha dimers is connected with formation or localization to the lipid rafts. Recruiting triggered TCR complexes to these membrane microdomains as well as affin-ity of TCR to MHC I is modulated by CD8, thereby affecting the functional diversity of the TCR signaling.

The UCHT-4 antibody recognises the CD8 alpha antigen on human cytotoxic/suppres-sor T cells. On flow cytometry it stains 14-45% of human peripheral blood mononuclear cells. CD8 is a disulfide-linked dimer and exists as a CD8 alpha homodimer or CD8 alpha-beta heterodimer (each monomer approx. 32-34 kDa). The antibody has been studied at the Third International Workshop on Human Leukocyte Differentiation Anti-gens. The antibody does not react with formaldehyde-fixed cells; negative in Western Blotting application.

The antibody MEM-31 recognises a conformationally-dependent epitope of CD8, a cell surface glycoprotein found on most cytotoxic T lymphocytes that mediates efficient cell-cell interactions within the immune system.

The HIT8a antibody recognises a 68-kDa type-I transmembrane glycoprotein that consists of two disulfide-linked chains that form alpha homodimers or alpha/beta heterodimers. The most frequent CD8 antigen is CD8 alpha/beta heterodimer, which is expressed on 13-48 % peripheral blood suppressor/cytotoxic T lymphocytes (Ts/Tc) and 70-80% thymocytes. In addition, a proportion of γδT cells and NK cells express CD8α homodimers. CD8β requires the presence of CD8 alpha to be expressed on the cell surface. CD8 antigen is coreceptor for HLA class-I molecules.



APC 05-7-134A 1 ml*

comment

CD9 belongs to proteins of the tetraspanin family that orchestrate cholesterol-associat-ed tetraspanin-enriched signaling microdomains within the plasma membrane, forming complexes with each other as well as with integrins, membrane-anchored growth factors and other proteins. CD9 is involved in cell motility, osteoclastogenesis, neurite outgrowth, myotube formation, and sperm-egg fusion, plays roles in cell attachment and proliferation and is necessary for association of heterologous MHC II molecules on the dendritic cell plasma membrane which is important for effective T cell stimulation. CD9 is also considered a metastasis suppressor in solid tumours.

The antibody MEM-61 recognises an epitope on the second extracellular domain (EC2) of CD9 antigen, a 24 kDa single transmembrane polypeptide expressed on platelets, monocytes, pre-B lymphocytes, granulocytes and activated T lymphocytes.


0.1 1 10 100 1000

500

400

300

200

100

0 cd8

Pe




cd10 Purified 005-7-137 100 µg IgG1 LT10 HuFITC 05-7-137F 1 ml*

PE 05-7-137P 1 ml*

APC 05-7-137A 1 ml*

comment

CD10 (neutral endopeptidase NEP, common acute lymphocytic leukaemia antigen CALLA, membrane metallo-endopeptidase MME, enkefalinase) is a 100-kDa cell surface zinc metalloprotease; cleaving peptide bonds on the N-terminus of hydrophobic amino acids and inactivating multiple physiologically active peptids. CD10 is expressed on various normal cell types, including lymphoid precursor cells, germinal centre B lymhocytes, and some epithelial cells, and its expression level serves as a marker for diagnostics of many carcinomas. CD10 is also a differentiation antigen for early B-lym-phoid progenitors in the B cell differentiation pathway and has a key role in regulation of growth, differentiation and signal transduction of many cellular systems.

The antibody LT10 reacts with CD10 antigen (CALLA- Common Acute Lymphatic Leu-kaemia Antigen), a 100 kDa type II integral membrane protein expressed on uncommit-ted precursors. It is also expressed on activated and proliferating B lymphocytes in the germinal centres and granulocytes.

cd11a Purified 05-7-139 100 µg IgG1 MEM-25 HuFITC 05-7-139F 1 ml*

PE 05-7-139P 1 ml*

APC 05-7-139A 1 ml*

comment

CD11a (LFA-1a) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the aLb2 integrin. CD11a is implicated in activation of LFA-1 complex. LFA-1 is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity confor-mation, which supports tight binding of LFA-1 to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. LFA-1 is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differen-tiation and proliferation and of T cell effector functions. Blocking of LFA-1 function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti-LFA-1 antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation; binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity.

The antibody MEM-25 reacts with CD11a (a-subunit of human LFA-1), a 170-180 kDa type I transmembrane glycoprotein expressed on B and T lymphocytes, monocytes, macro-phages, neutrophils, basophils and eosinophils.




cd11b Purified 05-7-492 100 µg IgG1 LT11 HuFITC 05-7-492F 1 ml*

Purified 05-7-140 100 µg IgG2a MEM-174 Hu

FITC 05-7-140F 1 ml*

PE 05-7-140P 1 ml*

comment

CD11b is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement coated particles. It is identical to CR3, the receptor for the iC3b fragment of the third complement compo-nent. It probably recognises the RGD peptide in C3b. CD11b is also a receptor of fibrino-gen gamma chain. The Mac1 CD11b antigen is present on macrophages, granulocytes, natural killer cells, blood monocytes. CD11b is expressed on 8% spleen cells, 44% bone marrow cells and less than 1% of thymocytes and is commonly used as a microglial marker in nervous tissue.

The antibody LT11 recognises CD11b antigen (Mac-1), a 165 kDa type I transmembrane protein mainly expressed on monocytes, granulocytes and NK cells. The CD11b medi-ates neutrophil and monocyte interactions with stimulated endothelium.

cd11c FITC 05-7-462F 1 ml* IgG1 BU15 HuPE 05-7-462P 1 ml*

APC 05-7-462A 1 ml*

comment

CD11c (p150, αX integrin subunit) forms a complex with CD18 (β2 integrin subunit) and is expressed mainly on tissue macrophages and dendritic cells. CD11c binds to comple-ment fragment iC3b, fibrinogen, VCAM-1 and ICAM-2 or e.g. CD90. Like other β2 integ-rins, CD11c/CD18 plays a role in cell migration and phagocytosis. Moreover, interaction of CD11c/CD18 with plasminogen regulates plasmin activities, and interaction with heparin counteracts binding of iC3b.

The antibody BU15 reacts with CD11c (αX, p150), a 150 kDa integrin expressed mainly on dendritic cells and tissue macrophages.

cd13 FITC 05-7-488F 1 ml* IgG1 WM-15 Hu, PriPE 05-7-488P 1 ml*

APC 05-7-488A 1 ml*

comment

CD13 (aminopeptidase N, APN) is a 150 kDa type II transmembrane zinc-binding ectopeptidase expressed on various cell types. This metalloprotease preferentially catalyses the removal of neutral amino acids from small peptides, thus activating or inactivating bioactive peptides. CD13 also has a role in extracellular matrix degradation, antigen processing and signal transduction, is important in inflammatory responses, regulates intercellular contact, cell motility and vascularisation. CD13 is involved in protection of leukaemic cells against apoptosis and its expression associated with poor prognosis of carcinomas.

The antibody WM-15 recognises the human CD13 cell surface glycoprotein, a 150 kDa molecule expressed on granulocytes, endothelial cells, epithelial cells and myeloid progenitors.




cd14 Purified 05-7-414 100 µg IgG1 18D11 Hu FITC 05-7-414F 1 ml*

PE 05-7-414P 1 ml*

APC 05-7-414A 1 ml*

Purified 05-7-143 100 µg IgG1 MEM-15 Hu

FITC 05-7-143F 1 ml*

PE 05-7-143P 1 ml*

PE-Dy647 05-7-143 PD 647 1 ml*

APC 05-7-143A 1 ml*

comment

CD14 is a 55 kDa GPI-anchored glycoprotein, constitutively expressed on the surface of mature monocytes, macrophages, and neutrophils, where serves as a multifunctional lipopolysaccharide receptor; it is also released into the serum both as a secreted and enzymatically cleaved GPI-anchored form. CD14 binds lipopolysaccharide molecules in a reaction catalysed by lipopolysaccharide-binding protein (LBP), an acute phase serum protein. The soluble sCD14 is able to discriminate slight structural differences between lipopolysaccharides and is important for neutralisation of serum allochthonous lipo-polysaccharides by reconstituted lipoprotein particles. CD14 affects allergic, inflamma-tory and infectious processes. The 18D11 antibody recognises the CD14 antigen (LPS receptor) expressed strongly on the surface of monocytes, weakly on the surface of granulocytes, macrophages, dendritic cells and B cells. On flow cytometry it stains > 90% of human peripheral blood monocytes. The antibody is LPS neutralising.

The antibody MEM-15 reacts with CD14, a 53-55 kDa GPI (glycosylphosphatidylinositol)-linked membrane glycoprotein expressed on monocytes, macrophages and weakly on granulocytes; also expressed by most tissue macrophages. The antibody MEM-15 also reacts with soluble forms of CD14 found in serum and in the urine of some nephrotic patients.

cd15 FITC 05-7-145F 1 ml* IgM MEM-158 HuPE 05-7-145P 1 ml*

comment

CD15 (Lewis X, Le(x); stage specific embryonic antigen-1, SSEA-1) is a trisacharide determinant (3- fucosyl-N-acetyllactosamine) expressed on several glycolipids, glycoproteins and proteoglycans of various cell types, e.g. granulocytes, mast cells, monocytes, macrophages, cells of gastric mucosa, nervous system and various tumour cells. There are several variants of Lewis x, such as sialyl-Lewis x or sulphated Lewis x. Cells with high surface expression of Le(x) antigen exhibit strong self- aggregation, based on calcium-dependent Le(x)-Le(x) interaction. This process is involved for example in embryo compaction or in autoaggregation of teratocarcinoma cells. Sialyl-Le(x) and its isomer sialyl-Le(a) are ligands of selectins. CD15 expression has been extensively used to confirm diagnosis of Hodgkins disease.

The antibody MEM-158 reacts with CD15, a cell membrane molecule 3-fucosyl-N-acetyl-lactosamine (3-FAL) strongly expressed on granulocytes, monocytes, macrophages, mast cells; it is also present on Langerhans cells and some myeloid precursors cells.


0.1 1 10 100 1000

500

400

300

200

100

0 cd1

4 fi

tc




cd16 FITC 05-7-514F 1 ml* IgG1 3G8 HuPE 05-7-514P 1 ml*

APC 05-7-514A 1 ml*

FITC 05-7-506F 1 ml* IgG1 HI16a Hu

comment

CD16 (FcγRIII) is a 50-80 kDa glycoprotein serving as a low affinity IgG receptor. Human FcγRIII is expressed in two forms FcγRIII-A and –B. FcγRIII-A is a transmembrane protein of monocytes, macrophages, NK cells and a subset of T cells. It is associated with the FcεRI-γ subunit and is responsible for antibody-dependent NK cell cytotoxicity. Mast cell FcγRIII-A is associated, moreover, with FcεRI-β subunit. Besides IgG, FcεRI-A can be triggered also by oligomeric IgE. FcγRIII-B is a GPI-linked monomeric receptor expressed on neutrophils and is involved in the activation and induction of a proadhesive phenotype.

The antibody 3G8 reacts with CD16, a low affinity receptor for aggregated IgG (FcγRIII antigen). CD16 exists in two different isoforms: CD16a (FcγRIIIA; 50-65 kDa; expressed on NK cells, monocytes and macrophages) and CD16b (FcγRIIIB; 48 kDa; mainly ex-pressed on neutrophils).

The antibody HI16a reacts with CD16, a low affinity receptor for aggregated IgG (FcγRIII antigen).

cd18 FITC 05-7-150F 1 ml* IgG1 MEM-48 Hu PE 05-7-150P 1 ml*

APC 05-7-150A 1 ml*

comment

CD18, integrin β2 subunit, forms heterodimers with four types of CD11 molecule to constitute leukocyte (β2) integrins: αLβ2 (CD11a/CD18, LFA-1), αMβ2 (CD11b/CD18, Mac-1, CR3), αXβ2 (CD11c/CD18) and αDβ2 (CD11d/CD18). In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits. These integrins are essential for proper leukocyte migration, mediating intercellular contacts. Absence of CD18 leads to leukocyte adhesion deficiency-1; severe reduction of CD18 expression leads to the development of a psoriasiform skin disease. CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin and is sufficient to mediate leukotoxin-mediated cytolysis.

The antibody MEM-48 recognises an epitope involving residues 534-546 in cysteine-rich repeat 3 of the CD18 antigen (integrin β2 subunit; β2 integrin). CD18 is a 90-95 kDa type I transmembrane protein expressed on all leukocytes. The antibody induces high-affinity conformation of LFA-1 complex.


0.1 1 10 100 1000

500

400

300

200

100

0 cd1

6 Pe





PE 05-7-153P 1 ml*

PE-Dy647 05-7-153 PD 647 1 ml*

APC 05-7-153A 1 ml*

FITC 05-7-507F 1 ml* IgG1 HIB19 Hu

comment

CD19 is a transmembrane glycoprotein of the Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease the B cell threshold for activation by the antigen. Besides being a signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a cen-tral regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.

The antibody LT19 reacts with CD19 (B4), a 95 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on B lymphocytes and follicular dendritic cells; it is lost on plasma cells.

cd20 Purified 05-7-155 100 µg IgG2a LT20 HuFITC 05-7-155F 1 ml*

PE 05-7-155P 1 ml*

PE-Dy647 05-7-155 PD 647 1 ml*

APC 05-7-155A 1 ml*

comment

CD20 is a cell surface 33-37 (depending on the degree of phosphorylation) kDa non-glycosylated surface phosphoprotein expressed on mature and most malignant B cells, but not stem cells or plasma cells (low number of CD20 has been also detected on a subpopulation of T lymphocytes and it can be expressed on follicular dendritic cells). Its expression on B cells is synchronous with the expression of surface IgM. CD20 regulates transmembrane calciumconductance (probably functioning as a component of store operated calcium channel), cell cycle progression and B cell proliferation. It is associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change and/or BCR (B cell antigen recep-tor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B cell malignancies, but does not become internalised or shed from the plasma membrane following mAb treatment.

The antibody LT20 reacts with CD20 (Bp35), a 33-37 kDa non-glycolysated membrane receptor with four transmembrane domains, expressed on B lymphocytes (it is lost on plasma cells), follicular dendritic cells, and at low levels on peripheral blood T lympho-cytes.


0.1 1 10 100 1000

500

400

300

200

100

0 cd1

9 fi

tc


0.1 1 10 100 1000

500

400

300

200

100

0 cd2

0 aP

cssc Analysed with CyFlow®



cd21 Purified 05-7-156 100µg IgG1 LT 21 Hu, Por, Bo, CanFITC 05-7-156F 1 ml*

PE 05-7-156P 1 ml*

APC 05-7-156A 1 ml*

comment

CD21 (complement receptor 2, CR2) binds C3 complement fragments, especially its breakdown fragments, which remain covalently attached to complement activating surfaces or antigens. CD21 has important roles in uptake and retention of immunocom-plexes, survival of memory B cells and in development and maintenance of the humoral response to T dependent antigens. CD21 also serves as a key receptor for Epstein-Barr virus binding and is involved in targeting prions to folicular dendritic cells and expedit-ing neuroinvasion following peripheral exposure to prions. A soluble form of the CD21 (sCD21) is shed from the lymphocyte surface and retains its ability to bind respective ligands.

The antibody LT21 reacts with CD21 (CR2), a 145 kDa transmembrane glycoprotein (complement C3d receptor – C3dR) expressed on B lymphocytes, follicular dendritic cells, some epithelial cells and a subset of T lymphocytes. It is not expressed on im-mature B cells.

cd22 Purified 05-7-157 100 µg IgG1 MEM-01 Hu, PriFITC 05-7-157F 1 ml*

PE 05-7-157P 1 ml*

APC 05-7-157A 1 ml*

comment

CD22, also known as Siglec-2 (sialic acid-binding immunoglobulin-like lectin-2) is a transmembrane glycoprotein binding alpha2,6-linked sialic acid-bearing ligands. Intracellular domain of CD22 recruits protein tyrosine phosphatase SHP-1 through the immunoreceptor tyrosine-based inhibitory motifs (ITIMs), thus setting a threshold for B cell receptor-mediated activation. CD22 also regulates B cell response by involvement in controlling the CD19/CD21-Src-family protein tyrosine kinase amplification pathway and CD40 signaling. CD22 exhibits hallmarks of clathrin-mediated endocytic pathway.

The antibody MEM-01 reacts with CD22 (BL-CAM), a 130 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed in the cytoplasm of pro-B and pre-B lymphocytes, and on the surface of mature and activated B lymphocytes; it is lost on plasma cells, peripheral blood T lymphocytes, granulocytes and monocytes. The antibody MEM-01 cross-blocks the antibody OTH228 that recognises uniquely epitope "E"; it does not cross-block antibodies RFB-4, CLB22/1 and CLB- BLy1.




cd25 Purified 05-7-159 100 µg IgG1 MEM-181 HuFITC 05-7-159F 1 ml*

PE 05-7-159P 1 ml*

PE-Dy647 05-7-159 PD 647 1 ml*

APC 05-7-159A 1 ml*

FITC 05-7-509F 1 ml*

comment

CD25 (IL2Ralpha, Tac) is a ligand-binding alpha subunit of interleukin 2 receptor (IL2R). Together with beta and gamma subunit CD25 constitues the high affinity IL2R, whereas CD25 alone serves as the low affinity IL2R. CD25 expression rapidly increases upon T cell activation. The 55 kDa CD25 molecule is enzymatically cleaved and shed from the cell surface as a soluble 45 kDa s-Tac, whose concentration in serum can be used as a marker of T cell activation. Expression of CD25 indicates the neoplastic phenotype of mast cells. Humanised anti CD25 antibodies represent a useful tool to reduce the incidence of allograft rejection as well as the severity of graft versus host reaction, and radioimmunoconjugates of anti-CD25 antibodies can be used against CD25 expressing lymphomas. The antibody MEM-181 reacts with CD25 (Interleukin-2 receptor α chain), a 55 kDa type I transmembrane glycoprotein expressed on activated B and T lymphocytes, activated monocytes/macrophages and on CD4+ T lymphocytes (T regulatory cells); it is lost on resting B and T lymphocytes.

The antibody HI25a reacts with CD25 (Interleukin-2 receptor α chain), a 55 kDa type I transmembrane glycoprotein expressed on activated B and T lymphocytes, activated monocytes/macrophages and on CD4+ T lymphocytes (T regulatory cells); it is lost on resting B and T lymphocytes. Antigen density of CD25 is upregulated by the stimulation of PHA, ConA and CD3 antibody.

cd27 Purified 05-7-161 100 µg IgG2a LT27 HuFITC 05-7-161F 1 ml*

PE 05-7-161P 1 ml*

APC 05-7-161A 1 ml*

comment

CD27 is a transmembrane 55 kDa protein of the nerve growth factor-receptor family, expressed as a disulfide-linked homodimer on mature thymocytes, peripheral blood T cells and a subpopulation of B cells. Activation of T cells via TCR-CD3 complex results in upregulation of CD27 expression on the plasma membrane as well as in the release of its soluble 28-32 kDa form, sCD27, detected in the plasma, urine or spinal fluid. This sCD27 is an important prognostic marker of acute and chronic B cell malignancies. RgpA, a cystein proteinase, although activating T cells through the protease-activated receptors (PARs), degradates CD27 and counteracts T cell activation mediated by CD27 and its ligand CD70.

The antibody LT27 reacts with CD27 (T14), a 50-55 kDa type I transmembrane glycopro-tein (member of the TNF-receptor superfamily) expressed on medullary thymocytes, peripheral T lymphocytes, some B lymphocytes and NK cells.




cd28 FITC 05-7-427F 1 ml* IgG1 KOLT-2 Hu

comment

The antibody was submitted to CD28 in the Third International Workshop on Human Leukocyte Differentiation Antigens. The monoclonal antibody is directed against the CD28-antigen, which is weakly expressed on human T cells in the resting period and strongly on human cytotoxic/suppressor T cells (molecular mass 44 kDa). The mono-clonal antibody also reacts with 30% of human thymocytes and adult T cell leukaemia. The monoclonal antibody does not react with normal human B lymphocytes, mono-cytes, granulocytes, platelets, erythrocytes, common acute lymphoblastic leukaemia cells or acute myelocytic leukaemia cells.

cd29 Purified 05-7-162 100 µg IgG1 MEM-101A Hu, Ms, PorFITC 05-7-162F 1 ml*

PE 05-7-162P 1 ml*

APC 05-7-162A 1 ml*

comment

CD29 (β1 integrin subunit, GPIIa) forms non-covalently linked heterodimers with at least 6 different α chains (α1-α6, CD49a-f) determining the binding properties of β1 (VLA) integrins. These integrins mediate cell adhesion to collagen, fibronectin, laminin and other extracellular matrix (ECM) components. This interaction hinders cell death, whereas disruption of anchorage to ECM leads to apoptosis. Decreased expression of most β1 integrins correlates with acquiring multidrug resistance of tumour cells during selection in presence of antitumour drug. In platelets, translocation of intracellular pool of β1 integrins to the plasma membrane following thrombin stimulation. These integrins are also up-regulated in leukocytes during emigration and extravascular migration and appear to be critically involved in regulating the immune cell trafficking from blood to tissue, as well as in regulating tissue damage and disease symptoms related to inflammatory bowel disease. Through a β1 integrin-dependent mechanism, fibronectin and type I collagen enhance cytokine secretion of human airway smooth muscle in response to IL-1β.

The antibody MEM-101A reacts with CD29 antigen (Integrin beta 1 chain), a 130 kDa single chain type I glycoprotein expressed as a heterodimer (non-covalently associated with the integrin alpha subunits 1-6). CD29 is broadly expressed on majority of haema-topoietic and non-haematopoietic cells (leukocytes, platelets, fibroblasts, endothelial cells, epithelial cells and mast cells).

cd30 Purified 05-7-163 100 µg IgG MEM-268

comment

The antibody MEM-268 recognises the extracellular part of CD30 (Ki- 1 antigen), a 105 kDa single chain glycoprotein expresses on Hodgkin's and Reed-Stemberg cells; it is also found in Burkitt’s lymphomas, virus-infected T and B lymphocytes; and on normal B und T lymphocytes after activation (T lymphocytes that produce Th2-type cytokines and on CD4+/CD8+ T lymphocytes that co-express CD45RO and the IL4 receptor).





APC 05-7-164A 1 ml*

comment

CD31 (platelet endothelial cell adhesion molecule-1, PECAM-1) is an inhibitory coreceptor involved in regulation of T cell and B cell signaling by a dual immunore-ceptor tyrosine-based inhibitory motif (ITIM) that upon associated kinases-mediated phosphorylation provide docking sites for protein-tyrosine phosphatases. CD31 is expressed ubiquitously within the vascular compartment and is located mainly at junctions between adjacent cells. N-terminal Ig-like domain of CD31 is responsible for its homophilic binding, which plays an important role in cell-cell interactions. CD31 is a multifunctional molecule with diverse roles in modulation of integrin-mediated cell adhesion, transendothelial migration, angiogenesis, apoptosis, negative regulation of immunoreceptor signaling, autoimmunity, macrophage phagocytosis, IgE-mediated anaphylaxis and thrombosis. It is one of the key regulatory molecules in the vascular system.

The antibody MEM-05 reacts with CD31 (PECAM-1), a 130-140 kDa type I transmem-brane glycoprotein expressed on monocytes, platelets, granulocytes, endothelial cells and stem cells of the myeloid lineage.

cd33 FITC 05-7-165F 1 ml* IgG1 HIM3-4 Hu, PriPE 05-7-165P 1 ml*

comment

CD33 is a transmembrane protein of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies; these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface. CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukaemia.

The antibody HIM3-4 reacts with CD33, a 67 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on myeloid progenitors, monocytes, granulo-cytes, dendritic cells and mast cells; it is absent on platelets, lymphocytes, erythro-cytes and haematopoietic stem cells.

cd34 Purified 05-7-495 100 µg IgG1 581 HuFITC 05-7-495F 1 ml*

PE 05-7-495P 1 ml*

APC 05-7-495A 1 ml*

comment

CD34 is a highly glycosylated monomeric 111-115 kDa surface protein, which is present on many stem cell populations. It is a well established stem cell marker, though its expression on human haematopoietic stem cells is reversible. CD34 probably serves as a surface receptor that undergoes receptor-mediated endocytosis and regulates adhesion, differentiation and proliferation of haematopoietic stem cells and other progenitors. CD34 expression is likely to represent a specific state of haematopoietic development that may have altered adhering properties with expanding and differen-tiating capabilities in both in vitro and in vivo conditions. This antibody recognises the class 3 epitope on the CD34 antigen on human haematopoietic precursor cells. On flow cytometry it stains > 95% of Kg1a-cells (human acute myelogenous leukaemia cell line). This antibody has been studied at the Fifth International Workshop on Human Leucocyte Differentiation Antigens.



0.1 1 10 100 1000

500

400

300

200

100

0 cd3

4 Pe


Gate: CD45+

cd34+



cd35 FITC 05-7-477F 1 ml* IgG1 UJ11 Hu

comment

The antibody UJ11 is directed against the CD35-antigen (CR1 antigen). CR1 is a comple-ment component receptor with specificity for C3b, C4b and iC3b. The antigen is a 220 kDa molecule with polymorphism in a low percentage of individuals, that results in mo-lecular forms of 250 and 220/250 kDa. The monoclonal antibody reacts with diverse cell types like: erythrocytes, B lymphocytes, monocytes, granulocytes, NK cells, follicular dendritic cells, some T cells and kidney podocytes.

cd36 Purified 05-7-167 100 µg IgG1 TR9 HuFITC 05-7-167F 1 ml*

PE 05-7-167P 1 ml*

APC 05-7-167A 1 ml*

comment

CD36 (fatty acid translocase, FAT) is an 88 kDa ditopic glycosylated protein that belongs to the class B family of scavenger receptors. CD36 is expressed by most resting marginal zone B cells but not by follicular and B1 B cells, and it is rapidly induced on Follicular B cells in vitro upon TLR and CD40 stimulation. CD36 does not affect the development of B cells, but modulates both primary and secondary antibody response. Similarly to glucose transporter GLUT4, CD36 is translocated from intracellular pools to the plasma membrane following cell stimulation by insulin. In mouse, CD36 is re-sponsible for gustatory perception of long-chain fatty acids.

The antibody TR9 reacts with CD36 (GPIIIb), a 85 kDa integral membrane glycoprotein expressed on platelets, macrophages, endothelial cells, early erythroid cells and megakaryocytes. The antibody TR9 cross-blocks binding of FITC-labeled standard anti-body OKM5. Anti-CD36 antibodies inhibit adhesive functions (e.g. adherence of infected erythrocytes to target cells).

cd37 FITC 05-7-417F 1 ml* IgG1 HH1 HuPE 05-7-417P 1 ml*

APC 05-7-417A 1 ml*

comment

This antibody recognises the CD37 antigen on human B cells. In flow cytometry it stains approximately 2-10% of human peripheral blood mononuclear cells strongly. This antibody has been studied at the Third International Workshop on Human Leukocyte Differentiation Antigens.

cd38 PE 05-7-168P 1 ml* IgG1 HIT2 HuAPC 05-7-168A 1 ml*

comment

CD38 (NAD+ glycohydrolase) is a type II transmembrane glycoprotein able to induce ac-tivation, proliferation and differentiation of mature lymphocytes and mediate apoptosis of myeloid and lymphoid progenitor cells. Another role of CD38 is provided by enzymatic activity of its extracellular part. CD38 acts as NAD+ glycohydrolase converting NAD+ into ADP-ribose, as ADP-ribosyl cyclase producing cADPR and as cADPR hydrolase, thus affecting levels of calcium-mobilizing metabolites. ADPR produced by CD38 serves as an important second messenger of neutrophil and dendritic cell migration.

The antibody HIT2 reacts with CD38 (T10), a 45 kDa type II transmembrane glycoprotein strongly expressed mainly on plasma cells and activated T and B lymphocytes; it is an antigenic marker of lymphoid cells.




cd40 FITC 05-7-170F 1 ml* IgG1 HI40a HuPE 05-7-170P 1 ml*

APC 05-7-170A 1 ml*

comment

CD40 is a costimulatory molecule of the TNF receptor superfamily and is expressed on many cell types, such as B cells, monocytes/macrophages, dendritic cells, endothelial cells, fibroblasts or vascular smooth muscle cells. Interaction of CD40 and its ligand CD154 (CD40L) is required for the generation of antibody responses to T-dependent antigens as well as for the development of germinal centers and memory B cells. In monocytes/macrophages CD40 engagement induces production of pro-inflammatory cytokines and chemokines. CD40-CD154 interactions are also critical for development of CD4 T cell-dependent effector functions. CD40 links innate and adaptive immune responses to bacterial stimuli and serves as an important regulator affecting functions of other costimulatory molecules.

The antibody HI40a recognises CD40 (BP50), a 48 kDa type I single chain transmem-brane glycoprotein expressed on normal and neoplastic B cells, but not on terminally differentiated plasma cells. CD40 antigen is also present on Hodgkin's and Reed-Sternberg cells, follicular dendritic cells, some macrophages, basal epithelial cells and endothelial cells.

cd41a FITC 05-7-173F 1 ml* IgG1 HIP8 Hu

comment

CD41a (platelet glycoprotein IIb) is composed of two subunits (120 kDa a, alpha and 23 kDa b, beta) that interact with CD61 in the presence of calcium to form a functional adhesive protein receptor. Upon blood vessel damage, this receptor binds to a variety of proteins including von Willebrand factor, fibrinogen, fibronectin and vitronectin. CD41 is mainly expressed on megakaryocyte-platelet lineage, but generally belongs to the antigens that are expressed during early stages of haematopoietic differentiation. The antibody HIP8 reacts with alpha (a) subunit of CD41 (heavy chain; 120 kDa). CD41 is mainly expressed on platelets and megakaryocytes.

The antibody HIP8 blocks platelet aggregation and completely inhibits ADP-, epineph-rine-, and collagen-induced platelet activation, and partially inhibits ristocetin- and thrombin-induced platelet activation. HIP8 is useful in the morphological and physi-ological studies of platelets and megakaryocytes.

cd42b FITC 05-7-175F 1 ml* IgG1 HIP1 Hu, PriPE 05-7-175P 1 ml*

APC 05-7-175A 1 ml*

comment

CD42b (GPIbα) composes together with GPIbβ, GPIX and GPV the GPIb-IX-V receptor complex critical in the process of platelet-rich thrombus formation by thethering the platelet to a thrombogenic surface. CD42b binds to von Willebrand factor (vWF) exposed at a site of vascular injury, as well as to thrombin, coagulation factors XI and XII, high molecular weight kininogen, TSP-1, integrin Mac-1 and P- selectin. The extracellular domain of CD42b by its interactions also contributes to metastasis.

The antibody HIP1 reacts with CD42b (GPIbα), a 135-145 kDa membrane glycoprotein expressed on platelets and megakaryocytes. CD42b and CD42c (GPIbβ) are composed in a disulfide linked heterodimer (CD42b/c; 160 kDa); CD42b/c forms a noncovalent complex with CD42a and CD42d. The antibody inhibits the ristocetin-dependent binding of von Willebrand Factor (vWF) to platelets and ristocetin-induced platelet agglutina-tion.





PE 05-7-176P 1 ml*

APC 05-7-176A 1 ml*

comment

CD43 (leukosialin, sialophorin) is a transmembrane mucin-like protein with high nega-tive charge, expressed on the surface of most haematopoietic cells. CD43 contributes to a repulsive barrier that interferes with cellular adhesion, however, in certain cases also promotes leukocyte aggregation. By interaction with actin-binding proteins ezrin and moesin CD43 plays a regulatory role in remodeling T- cell morphology and regulates cell-cell interactions during lymphocyte traffic. CD43 signaling both enhances LFA-1 adhesiveness and counteracts LFA-1 induction via other receptors. Expression of CD43 causes induction of functionally active tumour suppressor p53 protein, but in case of p53 and ARF defficiency CD43 promotes tumour proliferation and viability. It appears to be an important modulator of leukocyte functions.

The antibody MEM-59 recognises neuraminidase-sensitive epitope on CD43 (Leukosia-lin), a 95-135 kDa type I transmembrane glycoprotein (mucin-type) which is involved in lymphocyte activation. CD43 is expressed by platelets and at high levels on the surface of all leukocytes; it is negative on resting B lymphocytes and erythrocytes.

cd44 Purified 05-7-177 100 µg IgG2b MEM-85 HuFITC 05-7-177F 1 ml*

PE 05-7-177P 1 ml*

APC 05-7-177A 1 ml*

comment

CD44 is a transmembrane glycoprotein expressed on the surface of most cells, which serves as a receptor for hyaluronan. CD44 mediates angiogenesis, cell adhesion, prolif-eration and migration, it is thus important for lymphocyte activation, recirculation and homing, it can thus serve e.g. as a modulator of macrophage recruitment in response to pathogen. Although CD44 functions are essential for physiological activities of normal cells, elevated CD44 expression correlates with poor prognosis in many carcinomas, facilitating tumour growth and metastasis, antiapoptosis and directional motility of cancer cells.

The antibody MEM-85 reacts with both cell surface-expressed and soluble form of CD44 antigen (Phagocyte glycoprotein 1), a 80-95 kDa transmembrane glycoprotein (hyaladherin family) present on most of cells and tissues (leukocytes, endothelial cells, mesenchymal cells, etc.); it is negative on platelets and hepatocytes.





PE 05-7-179P 1 ml*

PE-Dy647 05-7-179 PD 647 1 ml*

APC 05-7-179A 1 ml*

FITC 05-7-435F 1 ml* IgG1 HI30 Hu

comment

CD45 (LCA, leukocyte common antigen) is a receptor-type protein tyrosine phosphatase ubiquitously expressed in all nucleated haematopoietic cells, comprising approximately 10% of all surface proteins in lymphocytes. CD45 glycoprotein is crucial in lymphocyte development and antigen signaling, serving as an important regulator of Src-family ki-nases. CD45 protein exists as multiple isoforms as a result of alternative splicing; these isoforms differ in their extracellular domains, whereas they share identical transmem-brane and cytoplasmic domains. These isoforms differ in their ability to translocate into the glycosphingolipid-enriched membrane domains and their expression depends on cell type and physiological state of the cell. Besides the role in immunoreceptor signal-ing, CD45 is important in promoting cell survival by modulating integrin-mediated sig-nal transduction pathway and is also involved in DNA fragmentation during apoptosis.

The antibody MEM-28 reacts with all alternative forms of human CD45 antigen (Leu-kocyte Common Antigen), a 180-220 kDa single chain type I transmembrane protein expressed at high level on all cells of haematopoietic origin, except erythrocytes and platelets.

The antibody HI30 reacts with all alternative forms of human CD45 antigen (Leukocyte Common Antigen), a 180-220 kDa single chain type I transmembrane protein expressed at high level on all cells of haematopoietic origin, except erythrocytes and platelets and non-haematopoietic tissues and cells. CD45 is critically required for T and B cell antigen receptor-mediated activation.


cd45ra Purified 05-7-182 100 µg IgG2b MEM-56 HuFITC 05-7-182F 1 ml*

PE 05-7-182P 1 ml*

APC 05-7-182A 1 ml*

FITC 05-7-510F 1 ml* IgG2a HI100 IgG2b

comment

CD45RA is a high molecular weight isoform of a receptor-type protein tyrosine phos-phatase, CD45 glycoprotein. CD45 is crucial in lymphocyte development and antigen signaling, serving as an important regulator of Src-family kinases, promotes cell survival by modulating integrin-mediated signal transduction pathway and is also involved in DNA fragmentation during apoptosis. CD45 isoforms differ in their extracel-lular domains, whereas they share identical transmembrane and cytoplasmic domains. These isoforms differ in their ability to translocate into the glycosphingolipid-enriched membrane domains and their expression depends on cell type and physiological state of the cell. CD45RA is expressed e.g. on native T cells and normal plasma cells.

The antibody MEM-56 reacts with CD45RA, a 205-220 kDa single chain type I glycopro-tein, variant of CD45 (CD45RA isoform). CD45RA is expressed on most of B lympho-cytes, resting and native T lymphocytes, medullar thymocytes and monocytes.

The antibody HI100 reacts with CD45RA, a 205-220 kDa single chain type I glycoprotein, variant of CD45 (CD45RA isoform). CD45RA is expressed on most of B lymphocytes, resting and native T lymphocytes, medullar thymocytes and monocytes.


0.1 1 10 100 1000

500

400

300

200

100

0 cd

45 P

e-d

y647




cd45rb FITC 05-7-183F 1 ml* IgG1 MEM-55 HuPE 05-7-183P 1 ml*

APC 05-7-183A 1 ml*

comment

CD45RB is a receptor-type protein tyrosine phosphatase, CD45 glycoprotein. CD45 is crucial in lymphocyte development and antigen signaling, serving as an important regu-lator of Src-family kinases. It promotes cell survival by modulating integrin-mediated signal transduction pathway and is also involved in DNA fragmentation during apopto-sis. CD45 isoforms differ in their extracellular domains, whereas they share identical transmembrane and cytoplasmic domains. These isoforms differ in their ability to translocate into the glycosphingolipid-enriched membrane domains and their expres-sion depends on cell type and physiological state of the cell. CD45RB is expressed e.g. in microglia and inflammatory cells.

The antibody MEM-55 recognises a siliadase-sensitive epitope of CD45RB, a 180-240 kDa single chain type I membrane glycoprotein, variant of CD45 (CD45RB isoform). CD45RB is expressed on a subset of T lymphocytes, B lymphocytes, monocytes, macro-phages, granulocytes and dendritic cells.

cd45ro FITC 05-7-436F 1 ml* IgG2a UCHL1 Hu

comment

CD45R0 is the shortest isoform of a receptor-type protein tyrosine phosphatase, CD45 glycoprotein. CD45 is crucial in lymphocyte development and antigen signaling, serving as an important regulator of Src-family kinases, promotes cell survival by modulating integrin-mediated signal transduction pathway and is also involved in DNA fragmenta-tion during apoptosis. CD45 isoforms differ in their extracellular domains, whereas they share identical transmembrane and cytoplasmic domains. These isoforms differ in their ability to translocate into the glycosphingolipid-enriched membrane domains and their expression depends on cell type and physiological state of the cell. CD45R0 is expressed e.g. on macrophages, CD8+ T cells, activated T cells and myeloma cells.CD45RO

The antibody UCHL1 recognises CD45RO, a 180 kDa low molecular weight isoform of the leukocyte common antigen (LCA). The antigen is expressed on a subset of memory/activated T cells and on cortical thymocytes.

cd49d FITC 05-7-469F 1 ml* IgG1 BU49 HuPE 05-7-469P 1 ml*

APC 05-7-469A 1 ml*

comment

CD49d is the receptor for VCAM-1, thrombospondin and fibronectin. It plays a role in ECM adhesion and in the movement and migration of lymphocyte subsets within the circulatory system. This makes CD49d clinically useful in studies of inflammatory responses, distribution of haematopoietic stem cells and tumour metastatic disperse-ment.

The antibody BU49 reacts with the kD VLA-alpha-4 chain (lymphocyte homing receptor), which is associated with the CD29 molecule in the VLA-4 complex. This complex stimu-lates (or co-stimulates) specific tyrosine phosphorylation on focal adhesion kinase, paxillin, p59fy/p56lck and other moieties. The antigen is expressed on ALL and AML cells, T and B cells, monocytes, thymocytes and Langerhans cells.The antibody does not react with human kidney or brain sections, but positively stains malignant melanoma cells.





APC 05-7-188A 1 ml*

comment

CD50 (intracellular adhesion molecule 3, ICAM-3) is a transmembrane glycoprotein ex-pressed by leukocytes, that serves as a counter-receptor for the lymphocyte function-associated antigen (LFA)-1 integrin. Besides functioning as an adhesive molecule that mediates e.g. the contact between T cells and antigen presenting cells, ICAM-3 regu-lates affinity of LFA-1 for ICAM-1 and induces T cell activation and proliferation. ICAM-3 plays an essential role in the initiation of the immune response both on T cells and antigen presenting cells and interacts also with CD209 (dendritic cell-specific ICAM-3-grabbing nonintegrin, DC-SIGN), a C-type lectin of dendritic cells and macrophages; this process is involved in dialogue between dendritic cells and granulocytes.

The antibody MEM-171 recognises an epitope in the D2 domain of CD50 (ICAM-3), a 120-130 kDa type I membrane protein (immunoglobulin supergene family) expressed on leukocytes, endothelial cells and Langerhans cells; it is negative on platelets and erythrocytes.

cd52 FITC 05-7-190F 1 ml* IgG2b HI186 HuPE 05-7-190P 1 ml*

comment

CD52 (CAMPATH-1, HE5) is a highly glycosylated GPI-anchored 21-28 kDa glycopeptide which is present at high levels on lymphocytes, macrophages, epithelial cells of male reproductive tract and mature sperm. Its 12-amino acid beckbone carries a complex N-linked carbohydrate moiety, which differs between sperm and leukocyte CD52, as well as the GPI anchor does. CD52 can be acquired by sperm cells from seminal plasma, where it is released by epithelial cells. Although CD52 is not an essential T cell costimulator, its triggering results in activation of normal human T cells. CD52 is a very good target for antibody/complement-mediated cell lysis.

The antibody HI186 reacts with CD52 (CAMPATH-1), a 21-28 kDa glycoprotein contain-ing a large N-linked carbohydrate moiety; the mature CD52 molecule is actually much smaller (approx. 8-9 kDa). CD52 is expressed at high levels on lymphocytes, mono-cytes/macrophages and in the male reproductive tract.

cd53 FITC 05-7-512F 1 ml* IgG1 HI29 Hu

comment

The antibody HI29 recognises a 32-40 kDa type III, tetraspan membrane glycoprotein called TM4. CD53 antigen appears to be the marker with the strictest specificity for haematopoietic cells expressing all leukocytes including plasma cells, but not on plate-lets, erythrocytes and non-haematopoietic cells. The antibody HI29 mediates signal transduction.




cd54 FITC 05-7-192F 1 ml* IgG2b 1H4 HuPE 05-7-192P 1 ml*

PE-Dy647 05-7-192 PD 647 1 ml*

APC 05-7-192A 1 ml*

comment

CD54 (ICAM-1) is a 90 kD member of the C2 subset of the immunoglobulin superfamily. It is a transmembrane molecule with 7 potential N-glycosylated sites, expressed on resting monocytes and endothelial cells and can be upregulated on many other cells, e.g. with lymphokines, on B- and T- lymphocytes, thymocytes, dendritic cells and also on keratinocytes, chondrocytes, as well as epithelial cells. CD54 mediates cell adhesion by binding to integrins CD11a/CD18 (LFA-1) and to CD11b/CD18 (Mac-1). The interaction of CD54 with LFA-1 enhances antigen-specific T cell activation.

The antibody 1H4 reacts with CD54 (ICAM-1), a 85-110 kDa type I transmembrane glyco-protein (receptor for rhinovirus) expressed on activated endothelial cells, T lympho-cytes, B lymphocytes, monocytes, macrophages, granulocytes and dendritic cells; the expression of CD54 is upregulated by activation.

cd55 FITC 05-7-195F 1 ml* IgM MEM-118 Hu

comment

CD55 (decay-accelerating factor, DAF) is a GPI-anchored membrane glycoprotein that protects autologous cells from classical and alternative pathway of complement cas-cade. Bidirectional interactions between CD55 and CD97 are involved in T cell regula-tion and CD55 can still regulate complement when bound to CD97. In tumours, besides protection against complement, CD55 promotes neoangiogenesis, tumourigenesis, invasiveness and evasion of apoptosis.

The antibody MEM-118 recognises an epitope in SCR4 domain of CD55 (Decay accelerat-ing factor, DAF), a 60-70 kDa glycosylphosphatidylinositol (GPI)-anchored single chain glycoprotein. CD55 is widely expressed on haematopoietic and on many non-haemato-poietic cells; it is weakly present on NK cells.

cd56 Purified 05-7-196 1 ml* IgG2a MEM-188 Hu, Ms, PorFITC 05-7-196F 1 ml*

PE 05-7-196P 1 ml*

APC 05-7-196A 1 ml*

FITC 05-7-511F 1 ml* IgG1 B-A19 Hu, Ms, Por

comment

CD56 (NCAM, neural cell adhesion molecule) is a transmembrane glycoprotein of im-munoglobulin family serving as adhesive molecule which is ubiquitously expressed in nervous system, usually as 120 kDa, 140 kDa or 180 kDa isoform, and it is also found on T cells and NK cells. Polysialic modification results in reduction of CD56-mediated cell adhesion and is involved in cell migration, axonal growth, pathfinding and synaptic plasticity. CD56 is a widely used neuroendocrine marker with a high sensitivity for neuroendocrine tumours and ovarian granulosa cell tumours.

The antibody MEM-188 reacts with a 180 kDa isoform of CD56 (NCAM) expressed in leukocytes. It has been suggested that the antibody MEM-188 could react with rhesus monkey lymphocytes. Reactivity with other NCAM isoforms has not been tested.

The antibody B-A19 reacts with a 180 kDa isoform of CD56 (NCAM) expressed in leuko-cytes. It has been suggested that the antibody B-A19 could react with rhesus monkey lymphocytes. Reactivity with other NCAM isoforms has not been tested.


0.1 1 10 100 1000

250

200

150

100

50

0 cd5

4 Pe


0.1 1 10 100 1000

500

400

300

200

100

0 cd5

6 Pe





comment

CD58 (LFA-3) is an immunoglobulin family adhesion molecule expressed by both haematopoietic and non-haematopoietic cells (often on antigen presenting cells) and serving as ligand of CD2. This interaction is important for T cell-mediated immunity. CD58 is expressed in transmembrane form and in GPI-anchored form; the later is con-stitutively associated with protein kinases whereas the transmembrane form activates kinase activity upon triggering. CD58 is a powerful tool for detection of minimal residual disease in acute lymphocytic leukaemia, and for the evaluation of liver damages related with hepatitis B.

The antibody MEM-63 reacts with CD58 (LFA-3), a 40-70 kDa glycoprotein distributed over many tissues, leukocytes, erythrocytes, endothelial cells, epithelial cells and fibroblasts. The antibody inhibits CD2/CD58 interactions.


APC 05-7-198A 1 ml*

comment

CD59 (Protectin) is a small (18-20 kDa) GPI-anchored ubiquitously expressed inhibi-tor of the membrane attack complex (MAC). It is thus the key regulator that preserves the autologous cells from terminal effector mechanism of the complement cascade. CD59 associates with C5b-8 complex and thereby counteracts appropriate formation of cytolytic pore within the plasma membrane. CD59 is also a low-affinity ligand of human CD2 and causes T cell costimulation.

The antibody MEM-43 reacts with well defined epitope (W40, R-53) on CD59 (Protectin), a 18-20 kDa glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed on all haematopoietic cells; it is widely present on cells in all tissues.

cd61 Purified 05-7-445 100µg IgG1 C17 HuFITC 05-7-445F 1 ml*

PE 05-7-445P 1 ml*

APC 05-7-445A 1 ml*

comment

CD61 (beta3 integrin) is a transmembrane glycoprotein, which associates with CD41 or CD51 molecules to form heterodimeric adhesion receptores. The CD41/CD61 complex is one of the earliest markers of the megakaryocytic lineage. It binds to fibronectin, fibrinogen and von Willebrand factor, and is involved in platelet aggregation. The CD51/CD61 complex has similar binding properties and is involved in modulating migration and survival of angiogenic endothelial cells. CD61 is a useful marker of megakaryo-blasts and megakaryoblastic leukaemias and inhibits binding of ligands (fibrinogen, fibronectin, etc.).




cd62l Purified 05-7-201 1 ml* IgG1 LT-TD180 HuFITC 05-7-201F 1 ml*

PE 05-7-201P 1 ml*

APC 05-7-201A 1 ml*

FITC F05-7-513F 1 ml* IgG1 HI62L Hu

comment

CD62L (L-selectin) is an adhesion glycoprotein that is constitutively expressed on the cell surface of leukocytes and mediates their homing to inflammatory sites and pe-ripheral lymph nodes by enabling rolling along the venular wall. CD62L is also involved in activation-induced neutrophil aggregation. Activation-dependent CD62L shedding, however, counteracts neutrophil rolling. CD62L has also signaling roles including en-hance of chemokine receptor expression. Similarly to CD62P, the major ligand of CD62L is PSGL-1 (P-selectin glycoprotein ligand-1).

The antibody LT-TD180 reacts with CD62L (L-selectin), a 74-95 kDa single chain type I glycoprotein expressed on most peripheral blood B lymphocytes, T lymphocytes, mono-cytes and granulocytes; it is also present on a subset of NK cells and certain haemato-poietic malignant cells.

The antibody HI62L recognises a 76 kDa type I glycoprotein, L-selectin, also called leucocyte endothelial cellular adhesion molecule-1 (LECAM-1). CD62L is expressed on most peripheral blood T cells, B cells, some NK cells, monocytes and neutrophils; it is also present on some splenic lymphocytes, bone marrow lymphocytes and myeloid cells, thymocytes and certain haematopoietic malignant cells. CD62L acts as the peripheral lymph node homing receptor, mediates lymphocytes homing to high endo-thelial venules (HEV) of peripheral lymphoid tissue and leucocytes rolling on activated endothelium at inflammatory sites.

cd62P FITC 05-7-203F 1 ml* IgG1 HI62P HuPE 05-7-203P 1 ml*

APC 05-7-203A 1 ml*

comment

CD62P (P-selectin) is an adhesion glycoprotein that is expressed on platelets and endothelial cells upon their activation. Interaction between CD62P and its mucin-like ligand PSGL-1 (P-selectin glycoprotein ligand-1) expressed on the microvilli of most leukocytes supports leukocyte rolling along postkapillary venules at the earliest time of inflammation. Both CD62P and PSGL-1 are extended glycoproteins that form homodi-mers. CD62P dimerisation is probably mediated through interactions of the transmem-brane domains and stabilises leukocyte tethering and rolling, probably by increasing rebinding within a bond cluster.

The antibody HI62P recognises CD62P (P-selectin), a 140 kDa single chain type I transmembrane glycoprotein present in secretory α-granules in platelets, in Weibel-Palade bodies in endothelial cells and in megakaryocytes; it is relocated to the plasma membrane upon activation.





APC 05-7-204A 1 ml*

comment

CD63 (LAMP-3, lysosome-associated membrane protein-3), a glycoprotein of tet-raspanin family, is present in late endosomes, lysosomes and secretory vesicles of various cell types. It is also present in the plasma membrane, usually following cell activation. Hence it has become a widely used basophil activation marker. In mast cells, however, CD63 exposition does not need their activation. CD63 interacts with integrins and affects phagocytosis and cell migration, it is also involved in H/K-ATPase trafficking regulation of ROMK1 channels. CD63 also serves as a T cell costimulation molecule. Expression of CD63 can be used for predicting the prognosis in earlier stages of carcinomas.

The antibody MEM-259 reacts with CD63 (LAMP-3), a 40-60 kDa tetraspan glycoprotein expressed by granulocytes, platelets, T cells, monocytes/macrophages and endothelial cells. Cell surface exposition of CD63 is usually activation-dependent. The antibody is useful for detection of activated platelets, neutrophils and basophils.

cd69 Purified 05-7-418 100µg IgG1k FN50 HuFITC 05-7-418F 1 ml*

PE 05-7-418P 1 ml*

APC 05-7-418A 1 ml*

comment

CD69 (C-type lectin domain family 2 C, CLEC2C, also known as AIM) is one of the earliest inducible cell surface molecules acquired during leukocyte activation. This glycoprotein serves as a lectin-type receptor in lymphocytes, NK cells and platelets; it is involved in lymphocyte proliferation. CD69 expression is counteracted on T cells in the AIDS stage of HIV infection, and may be also predictive for clinical response to chemoimmunotherapy.

The antibody FN50 recognises CD69, a lymphocyte early activation marker.


APC 05-7-205A 1 ml*

comment

CD71 (transferrin receptor) is a type II transmembrane glycoprotein expressed as homodimer in erythroid blood cell line and in activated leukocytes. Upon binding of holotransferrin (complex of transferrin and iron ions) CD71 is internalised by clathrin-mediated endocytosis. Acidification of endosomes by vesicular membrane proton pumps leads to dissociation of iron ions, whereas transferrin (apotransferrin) remains associated with CD71 and recycles to the cell surface, where it is released upon expo-sure to normal pH. CD71 is also involved in uptake of non-transferrin bound iron.

The antibody MEM-75 reacts with CD71 antigen (transferrin receptor), a 95 kDa type II homodimeric transmembrane glycoprotein expressed on activated B and T lympho-cytes, macrophages and erythroid precursors; it is lost on resting blood leukocytes. The antibody MEM-75 does not block binding of transferrin to the receptor.




cd72 FITC 05-7-207F 1 ml* IgG2b 3F3 Hu PE 05-7-207P 1 ml*

comment

CD72 is a transmembrane glycoprotein expressed as a homodimer especially in B cells, but also in other antigen presenting cells such as dendritic cells and macrophages. Through one of its immunoreceptor tyrosine-based inhibitory motives (ITIMs), CD72 interacts with tyrosine phosphatase SHP-1, thereby suppressing B cell responsive-ness. Binding of CD72 with its ligand CD100 (Sema4D) prevents BCR association and phosphorylation of CD72 and results in dissociation of SHP-1 from CD72, thus enables B cell activation. The antibody 3F3 reacts with CD72, a 39-43 kDa type II membrane glycoprotein (C-type lectin family). CD72 is a pan-B cell marker expressed throughout the B lymphocytes differentiation with the exception of plasma cells; it is also present on follicular den-dritic cells.

cd74 FITC 05-7-455F 1 ml* IgG1 BU45 Hu

comment

CD74 recognises the cell surface expressed MHC Type II associated invariant chain molecule (33, 35, 41 kDa) present on B cells, activated T cells and epithelial cells. The BU45 epitop is a distinct determinant found distal from the C-terminus within the extra-cytoplasmatic domain of the CD74 antigen. It can be used to distinguish B cell lympho-mas from T cell lymphomas. The different stages of B cell maturation are all positive with BU45 including pre-B, ALL, B-CLL and Hairy Cell Leukaemia. Similary mononu-clear Hodgkin and Reed-Sternburg cells stain positive with anti CD74 antibodies.In non-lymphoid neoplasia CD74 expression is seen in epithelial tumours such as adenocarcinoma of the uterus, transitional cell carcinoma of the bladder and lung squamous cell carcinoma. The antibody BU45 is specific to CD74. This antibody does not cross react with canine tissue.

cd79a Purified 05-7-497 100µg IgG1 HM57 Hu

comment

The antibody HM57 interacts with CD79a (Igα), a 40-45 kDa subunit of B cell antigen-specific receptor (BCR) and its early developmental forms.





PE 05-7-208P 1 ml*

APC 05-7-208A 1 ml*

comment

CD80 (B7-1) and CD86 (B7-2) are ligands of T cell critical costimulatory molecule CD28 and of an inhibitory receptor CTLA-4 (CD152). Both B7 molecules are expressed on professional antigen-presenting cells and are essential for T cell activation, they can substitute each other in this process. The question what are the differences in CD80 and CD86 competency has not been fully elucidated yet; there are still conflicts in results about their respective roles in initiation or sustaining of the T cell immune response.

The antibody MEM-233 reacts with CD80 (B7-1), a 60 kDa single chain type I glycoprotein of immunoglobulin supergene family, expressed on professional antigen-presenting cells, such as dendritic cells, macrophages or activated B lymphocytes.


comment

CD80 (B7-1) and CD86 (B7-2) are ligands of T cell critical costimulatory molecule CD28 and of an inhibitory receptor CTLA-4 (CD152). Both B7 molecules are expressed on professional antigen- presenting cells and are essential for T cell activation, they can substitute each other in this process. The question what are the differences in CD80 and CD86 competency has not been fully elucidated yet; there are still conflicts in results about their respective roles in initiation or sustaining of the T cell immune response.

The antibody BU63 reacts with CD86 (B7-2), a 70 kDa type I transmembrane glycopro-tein of immunoglobulin supergene family, expressed on professional antigen-present-ing cells, such as dendritic cells, macrophages or activated B lymphocytes.


PE 05-7-209P 1 ml*

comment

CD95 (Fas, APO-1), a 46 kDa transmembrane glycoprotein, is a cell death receptor of the TNFR superfamily. Stimulation of CD95 results in aggregation of its intracellular death domains, formation of the death-inducing signaling complex (DISC) and activation of caspases. In type I cells caspase 3 is activated by high amounts of caspase 8 generated at the DISC, in type II cells low concentration of caspase 8 activates pathway leading to the release of cytochrome c from mitochondria and activation of caspase 3 by cytochom c. Besides its roles in induction of apoptosis, Fas also triggers pro-inflammatory cyto-kine responses.

The antibody LT95 reacts with CD95 (Fas/APO-1), a 46 kDa single chain type I glycopro-tein of the tumour necrosis factor/nerve growth factor (TNF/NGF) receptor superfamily, expressed on a variety of normal and neoplastic cells. It seems that the antibody LT95 does not induce Fas mediated apoptosis, although it cross-blocks anti-Fas DX2 antibody that recognises a functional epitope of Fas molecule.





comment

CD97 is a G-protein-coupled seven-span transmembrane adhesive receptor that is con-stitutively expressed on granulocytes and monocytes and rapidly upregulated on T and B cells upon activation. CD97 is produced in alternatively spliced forms and its cellular ligand is CD55 (DAF), which protects various cell types from complement-mediated damage. Interaction of CD97 on leukocytes and CD55 on vessel cells probably facilitate leukocyte activation and migration into the tissues, similarly, CD97 seems to play a role in tumour migration and invasiveness. CD97 is involved in T cell regulation and periph-eral granulocyte homeostasis.

The antibody MEM-180 recognises an unique epitope on CD97, a 75-85 kDa surface glycoprotein of G-protein-coupled receptor family, expressed on activated B and T lym-phocytes, monocytes/macrophages, dendritic cells and granulocytes.


comment

CD98 (4F2) is a type II transmembrane glycoprotein which serves as the heavy chain of the heterodimeric amino acid transporters (HATs). CD98, linked to various light chains by disulfide bond, is responsible for cell surface expression and basolateral localiza-tion of this transporter complex in polarised epithelial cells and also interacts with β1 integrins and increases their affinity for ligand. Besides its roles in amino acid trans-port, CD98 is thus involved in cell fusion and activation. It is implicated in regulation of cellular differentiation, growth and apoptosis.

The antibody MEM-108 reacts with CD98, a 125 kDa disulfide-linked heterodimer (80 kDa glycosylated heavy chain + 45 kDa non-glykosylated light chain). CD98 is expressed on T lymphocytes (upon activation) and activated NK cells; it is also present at low levels on B lymphocytes, NK cells, monocytes and platelets.

cd99r Purified 05-7-213 100 µg IgGM MEM-131 HuFITC 05-7-213F 1 ml*

comment

CD99 (E2, MIC2) is a transmembrane glycoprotein that is involved in regulation of T cell addhesive properties and programmed cell death distinct from typical apoptosis course. CD99 roles are specific to certain stages of T cell differentiation such as corti-cothymocytes. CD99R isoform expression is restricted in the haematopoietic system to T, NK and myeloid cells.

The antibody MEM-131 reacts with CD99R, an epitope restricted to a subset of CD99 molecule expressed on myeloid cells, NK cells and T lymphocytes.




cd105 Purified 05-7-214 100 µg IgG2a MEM-226 HuFITC 05-7-214F 1 ml*

PE 05-7-214P 1 ml*

APC 05-7-214A 1 ml*

comment

CD105 (Endoglin) is a homodimeric transmembrane glycoprotein serving in presence of TGFβR-2 as a receptor for TGFβ-1 and TGFβ-3. CD105 is highly expressed on endothelial cells and promotes angiogenesis during wound healing, infarcts and in a wide range of tumours. Its gene expression is stimulated by hypoxia. CD105 prevents apoptosis in hy-poxic endothelial cells and also antagonises the inhibitory effects of TGFβ-1 on vascular endothelial cell growth and migration. Normal cellular levels of CD105 are required for formation of new blood vessels.

The antibody MEM-226 reacts with CD105 (Endoglin), a 180 kDa type I homodimeris-ing membrane glycoprotein expressed on vascular endothelial cells (small and large vessels), activated monocytes and tissue macrophages, stromal cells of certain tissues including bone marrow, pre-B lymphocytes in fetal marrow and erythroid precursors in fetal and adult bone marrow; it is also present on syncytiotrophoblast on placenta throughout pregnancy.

cd108 FITC 05-7-216F 1 ml* IgM MEM-150 Hu

comment

CD108 (Sema7A) is a GPI-anchored semaphorin family member, which enhances central and peripheral axonal growth and is required for proper axon track formation during ebryogenesis. CD108 also regulates osteoclast differentiation and pre-osteoblastic cell migration. In the immune system it affects cell proliferation, chemotaxis and cytokine release. On erythrocytes CD108 defines the JMH (John-Milton-Hagen) human blood group. CD108 signalises through its receptors – plexin C1 and β1 integrins.

The antibody MEM-150 reacts with CD108 (JMH blood group antigen), a 80 kDa GPI-anchored glycoprotein expressed on various cell types including erythrocytes, lympho-blasts; at low levels it is present on circulating lymphocytes.

cd138 FITC 05-7-493F 1 ml* IgG1 B-A38 Hu

comment

CD138 (syndecan 1) is a transmembrane proteoglycan that can bind a variety of cytokines and modulate their activity, as well as the activity of extracellular matrix com-ponents and influence many developmental processes. CD138 is expressed mainly in differentiating keratinocytes and is transiently upregulated in all layers of the epidermis upon tissue injury. It is also highly expressed on plasma cells and can be detected even on fibroblasts, vascular smooth muscle cells and endothelial cells. Up-regulation and down-regulation of CD138 on the cell surface often correlates with the gain of cancerous characteristics. Serum levels of the shedded soluble sCD138 are used as a prognostic factor of cancerogenesis.

The antibody B-A38 recognises CD138 (syndecan 1), a 65-70 kDa heparan sulfate proteoglycan expressed mainly in the epidermis and plasma cells, but also in growth factor-stimulated lymphocytes.





comment

CD139 is found on peripheral blood cells, monocytes, granulocytes and is weakly ex-pressed on erythrocytes. Shows some reactivity with the smooth muscle of some blood vessels.

The monoclonal antibody BU30 reacts with the 228 kDa CD139 antigen under native (non-reducing) conditions. Histologically, there is a strong reactivity with renal glom-eruli and follicular dendritic cells.

cd147 Purified 05-7-217 100 µg IgG1 MEM-M6/1 HuFITC 05-7-217F 1 ml*

PE 05-7-217P 1 ml*

APC 05-7-217A 1 ml*

comment

CD147 (basigin, neurothelin, OX-47, 5A11, CE9, M6) also known as EMMPRIN (extracel-lular matrix metalloproteinase inducer) or TCSF (tumour cell-derived collagenase-stimulatory factor) is an ubiquitously expressed cell surface protein with multiple glyco-sylated forms. The highest level of CD147 expression is on metabolically active cells, such as lymphoblasts, inflammatory cells, brown adipocytes and malignant tumour cells. CD147 has multiple functions, including facilitating of cell surface expression of monocarboxylate transporter proteins and extracellular matrix metalloproteinases, regulation of integrin functions, it plays roles in cell development and activation, fetal development or retinal function.

The antibody MEM-M6/1 recognises an epitope in the N-terminal Ig domain (

Date post:	19-Oct-2020
Category:	Documents
Upload:	others
View:	0 times
Download:	0 times

PAR 1960 Reagenzienkatalog 2013-05-14 · cyflow ® counter Dedicated CD4 and CD4% counter for...

Documents